Older People's Unit, Royal United Hospital NHS Foundation Trust, Bath, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Trials. 2022 Oct 28;23(1):912. doi: 10.1186/s13063-022-06827-3.
Bladder symptoms are common in Parkinson's disease (PD), affecting half of all individuals. These have significant impact on quality of life as well as implications for morbidity, contributing to falls and hospital admission. The treatment of bladder symptoms can be complicated by the tendency to side-effects in people with PD including cognitive impairment and gait instability with anti-muscarinics. The development of new, better treatments is therefore warranted. Tibial nerve stimulation is a form of neuromodulation demonstrated to improve overactive bladder symptoms in non-neurogenic cohorts. Previously requiring hospital attendance, we aim to explore the use of this intervention using a simple device that can be used by patients at home.
STRIPE is a phase II randomised control trial of tibial nerve stimulation delivered by the Geko™ device, a small, self-adhesive neuromuscular stimulation device currently used for thromboembolism prophylaxis post-surgery. Active tibial nerve stimulation will be compared to sham stimulation, with participants blinded to treatment allocation and undertaking outcome assessment whilst still blinded. Participants will be asked to self-administer stimulation at home twice per week, for 30 min per session, over the course of 3 months. Primary outcome measure will be the International Consultation on Incontinence Overactive Bladder Questionnaire (OAB) at week 12. Secondary outcomes will include pre- and post-intervention bladder diary (frequency, urgency episodes, nocturia), patient perception of global change, bowel function and bladder-related quality of life. Participants will be recruited from the Proactive Integrated Management and Empowerment (PRIME) cross-sectional trial in which participants have been screened for bladder symptoms and invited to take part, as well as clinician referral from around the region.
This trial will involve a randomised control trial of a novel and easy to use method of delivering tibial nerve stimulation for PD in the patient's own home. This may potentially have huge benefit, avoiding the problems with side effects that can be seen with anti-muscarinics and providing a new potential modality of treatment.
ISRCTN11484954. Registered on 22 June 2021.
膀胱症状在帕金森病(PD)中很常见,影响所有患者的一半。这些症状对生活质量有重大影响,也会导致发病率增加,增加跌倒和住院的风险。由于 PD 患者容易出现副作用,如认知障碍和步态不稳定,抗毒蕈碱药物的治疗可能会变得复杂。因此,有必要开发新的、更好的治疗方法。胫神经刺激是一种神经调节形式,已被证明可改善非神经源性队列的膀胱过度活动症症状。以前需要住院治疗,我们旨在探索使用一种简单的设备,患者可以在家中使用这种干预措施。
STRIPE 是一项使用 Geko™ 设备(一种小型、自粘神经肌肉刺激设备,目前用于手术后预防血栓栓塞)进行胫神经刺激的 II 期随机对照试验。主动胫神经刺激将与假刺激进行比较,参与者对治疗分配保持盲态,并在保持盲态的情况下进行结果评估。参与者将被要求在家中每周自我管理两次刺激,每次 30 分钟,持续 3 个月。主要结局指标将是第 12 周的国际尿失禁咨询问卷(OAB)。次要结局指标将包括膀胱日记(频率、尿急发作、夜尿)、患者对整体变化的感知、肠道功能和膀胱相关生活质量的预干预和干预后变化。参与者将从 Proactive Integrated Management and Empowerment(PRIME)横断面试验中招募,该试验对膀胱症状进行了筛查,并邀请参与者参加,以及该地区的临床医生转诊。
本试验将涉及一项在患者家中使用新型、易于使用的方法进行胫神经刺激治疗 PD 的随机对照试验。这可能具有巨大的益处,可以避免抗毒蕈碱药物治疗中可能出现的副作用问题,并提供一种新的潜在治疗方式。
ISRCTN81501345。于 2021 年 6 月 22 日注册。